Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 7/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
| ▸ | AKT2 | P31751 | 2/20 | 0.40 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | BRS3 | P32247 | 5/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5783737 | 0.79 | BDKRB1 (0.51) | BDKRB1 | |
| SCHEMBL4985691 | 0.72 | BDKRB1 (0.55) | BDKRB1 | |
| SCHEMBL27656817 | 0.72 | BDKRB1 (0.55) | BDKRB1 | |
| SCHEMBL5783113 | 0.70 | BDKRB1 (0.52) | BDKRB1 | |
| SCHEMBL5782528 | 0.70 | BDKRB1 (0.64) | BDKRB1 | |
| SCHEMBL5782125 | 0.70 | BDKRB1 (0.63) | BDKRB1 | |
| SCHEMBL7930737 | 0.69 | MEN1 (0.50) | BRS3 | |
| SCHEMBL5560681 | 0.69 | HDAC3 (0.59) | PDE2A | |
| SCHEMBL5043487 | 0.69 | HDAC3 (0.59) | PDE2A | |
| SCHEMBL1927711 | 0.69 | FOLH1 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091380-B2 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1476419-B1 | N-BIPHENYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES | MERCK & CO INC (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1501787-B1 | N-BIPHENYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES WITH A SUBSTIITUENT ON THE METHYL USEFUL AS BRADYKININ ANTAGONISTS | MERCK & CO INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6919343-B2 | N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives | MERCK & CO., INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050085667-A1 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives | MERCK SHARP & DOHME LLC | 2005-04-21 | — | — | US | disclosed |
| US-20050084463-A1 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists | WOOD MICHAEL R (US) | 2005-04-21 | — | — | US | disclosed |
| US-20030220375-A1 | N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives | MERCK SHARP & DOHME LLC | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220375-A1 | N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives | BDKRB1, BDKRB2, CNR2 | BDKRB1 1/4885ROCK2 3219/4885AKT1 1827/4885 |
| US-20050084463-A1 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists | BDKRB1, BDKRB2, CNR2 | BDKRB1 1/4885ROCK2 3234/4885AKT1 1805/4885 |
| US-20050085667-A1 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives | BDKRB1, BDKRB2, LTB4R2 | BDKRB1 1/4885ROCK2 3354/4885AKT1 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.